Login to Your Account

Intellia files for IPO, inks $125M deal with Regeneron

By Michael Fitzhugh
Staff Writer

Tuesday, April 12, 2016

Intellia Therapeutics Inc., a gene-editing start-up that filed for a proposed $120 million IPO on Monday, added a new partnership with Regeneron Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription